ReviewJournal of gastrointestinal oncology2018
Advances in surgery for pancreatic cancer.
Review in Journal of gastrointestinal oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 16 citations in OpenAlex.
- Multifaceted Sulfonamide-Derived Thiosemicarbazones: Combining Metal Chelation and Carbonic Anhydrases Inhibition in Anticancer Therapy.International journal of molecular sciences · 2025Article
- Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma.JCO clinical cancer informatics · 2023Article
- Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis.The Indian journal of medical research · 2023Article
- Patient Perceptions of Decision-making and Quality-of-life Following Surgical Resection of Pancreatic Adenocarcinoma: A Mixed-methods Study.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2022Article
- Editorial.Indian journal of surgical oncology · 2019Article
- Pancreas cancer, careful improvements and human connections.Journal of gastrointestinal oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past 135 years, the field of pancreatic surgery for treatment of pancreatic malignancies has been a challenge to the surgical community. Originally filled with unacceptably high morbidity and mortality, these obstacles have been overcome through the work of numerous great surgeons in recent decades. Today, despite the improved safety of operating on the pancreas, patients still suffer from high rates of malignant recurrence and poor overall survival. Recent advances in pancreatic surgery aim to further improve the morbidity of these operations while increasing the number of patients who are both candidates for surgical resection and those who receive complete resections. This review focuses on recent literature describing the pros and cons of minimally invasive approaches to pancreatic surgery and the risks and benefits of vascular reconstruction to improve resectability. Both topics are currently debated amongst pancreatic surgeons and this article summarizes the varied viewpoints and their impact on outcomes in pancreas cancer surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.